CNTA Quote, Financials, Valuation and Earnings

AstraZeneca PLC has a net margin of -- compared to Centessa Pharmaceuticals PLC's net margin of 10.54%. Centessa Pharmaceuticals PLC's return on equity of -- beat AstraZeneca PLC's return on equity of 16.72%.

Centessa Pharmaceuticals PLC has a consensus price target of $28.57, signalling upside risk potential of 70.68%. On the other hand AstraZeneca PLC has an analysts' consensus of $90.46 which suggests that it could grow by 31.67%. Given that Centessa Pharmaceuticals PLC has higher upside potential than AstraZeneca PLC, analysts believe Centessa Pharmaceuticals PLC is more attractive than AstraZeneca PLC.

Centessa Pharmaceuticals PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AstraZeneca PLC has a beta of 0.455, suggesting its less volatile than the S&P 500 by 54.454%.

Centessa Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AstraZeneca PLC offers a yield of 2.22% to investors and pays a quarterly dividend of $0.50 per share. Centessa Pharmaceuticals PLC pays -- of its earnings as a dividend. AstraZeneca PLC pays out 75.25% of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Centessa Pharmaceuticals PLC quarterly revenues are --, which are smaller than AstraZeneca PLC quarterly revenues of $13.6B. Centessa Pharmaceuticals PLC's net income of -$42.6M is lower than AstraZeneca PLC's net income of $1.4B. Notably, Centessa Pharmaceuticals PLC's price-to-earnings ratio is -- while AstraZeneca PLC's PE ratio is 32.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Centessa Pharmaceuticals PLC is -- versus 4.08x for AstraZeneca PLC. Usually stocks with elevated PS ratios are considered overvalued.

Biodexa Pharmaceuticals PLC has a net margin of -- compared to Centessa Pharmaceuticals PLC's net margin of --. Centessa Pharmaceuticals PLC's return on equity of -- beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.

Centessa Pharmaceuticals PLC has a consensus price target of $28.57, signalling upside risk potential of 70.68%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 303.85%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Centessa Pharmaceuticals PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Centessa Pharmaceuticals PLC.

Centessa Pharmaceuticals PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.460, suggesting its more volatile than the S&P 500 by 46.046%.

Centessa Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Centessa Pharmaceuticals PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Centessa Pharmaceuticals PLC quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals PLC quarterly revenues of --. Centessa Pharmaceuticals PLC's net income of -$42.6M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Centessa Pharmaceuticals PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Centessa Pharmaceuticals PLC is -- versus 4.01x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Roivant Sciences has a net margin of -- compared to Centessa Pharmaceuticals PLC's net margin of -5143.78%. Centessa Pharmaceuticals PLC's return on equity of -- beat Roivant Sciences's return on equity of 93.1%.

Centessa Pharmaceuticals PLC has a consensus price target of $28.57, signalling upside risk potential of 70.68%. On the other hand Roivant Sciences has an analysts' consensus of $16.14 which suggests that it could grow by 40.25%. Given that Centessa Pharmaceuticals PLC has higher upside potential than Roivant Sciences, analysts believe Centessa Pharmaceuticals PLC is more attractive than Roivant Sciences.

Centessa Pharmaceuticals PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Roivant Sciences has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Centessa Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Roivant Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Centessa Pharmaceuticals PLC pays -- of its earnings as a dividend. Roivant Sciences pays out -- of its earnings as a dividend.

Centessa Pharmaceuticals PLC quarterly revenues are --, which are smaller than Roivant Sciences quarterly revenues of $4.5M. Centessa Pharmaceuticals PLC's net income of -$42.6M is higher than Roivant Sciences's net income of -$230.2M. Notably, Centessa Pharmaceuticals PLC's price-to-earnings ratio is -- while Roivant Sciences's PE ratio is 2.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Centessa Pharmaceuticals PLC is -- versus 73.56x for Roivant Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Verona Pharma PLC has a net margin of -- compared to Centessa Pharmaceuticals PLC's net margin of -763.91%. Centessa Pharmaceuticals PLC's return on equity of -- beat Verona Pharma PLC's return on equity of -74.15%.

Centessa Pharmaceuticals PLC has a consensus price target of $28.57, signalling upside risk potential of 70.68%. On the other hand Verona Pharma PLC has an analysts' consensus of $47.29 which suggests that it could grow by 5.53%. Given that Centessa Pharmaceuticals PLC has higher upside potential than Verona Pharma PLC, analysts believe Centessa Pharmaceuticals PLC is more attractive than Verona Pharma PLC.

Centessa Pharmaceuticals PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.400, suggesting its less volatile than the S&P 500 by 60.012%.

Centessa Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Centessa Pharmaceuticals PLC pays -- of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.

Centessa Pharmaceuticals PLC quarterly revenues are --, which are smaller than Verona Pharma PLC quarterly revenues of $5.6M. Centessa Pharmaceuticals PLC's net income of -$42.6M is higher than Verona Pharma PLC's net income of -$43M. Notably, Centessa Pharmaceuticals PLC's price-to-earnings ratio is -- while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Centessa Pharmaceuticals PLC is -- versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.